Research & Development in
Epalinges
32 companies in Research & Development based in Epalinges — name and year of registration from the commercial register. The list below shows them all.
All 32 companies in Epalinges
Cross-border Research Association
Since 2005 · 11–20 empl.
The core activity of TAPA EMEA is to improve supply chain security, particularly by connecting experts and developing educational materials to support companies in securing their supply chains.
PRECLIN Biosystems SA
Since 2008 · 1–10 empl.
PRECLIN Biosystems SA provides a comprehensive in vivo preclinical testing platform for the identification and validation of lead therapeutic candidates and specializes in preclinical models of chronic inflammatory and infectious diseases.
Novassay SA
Since 2013 · 11–20 empl.
The core activity of CentOS is the development and provision of a stable, predictable, manageable and reproducible Linux distribution based on the sources of Red Hat Enterprise Linux (RHEL).
Combioxin SA
Since 2015 · 11–20 empl.
The core activity of Combioxin SA is the development of life-saving medications for severe infections, particularly for the treatment of severe bacterial pneumonias. The company focuses on the development of innovative therapeutics, such as CAL02, a first-in-class anti-toxin agent used to neutralize virulence factors that play a crucial role in the development of organ failure and fatal complications in severe infections.
Sylex SA
Since 2016 · 1–10 empl.
Sylex SA provides the Sylex Health platform, a cloud-based eHealth solution for capturing, aggregating and managing electronic health records and integrating healthcare data and third‑party applications. The platform includes modules for EHR, public health management, hospital information management, patient portal access and AI clinical decision support, and supports common interoperability standards.
OCULIGHT dynamics Sàrl
Since 2018 · 1–10 empl.
OCULIGHT dynamics Sàrl provides daylight consulting and simulation‑based analyses to assess the effects of natural light on occupant well‑being. The company develops in‑house software (OCUSKY, OCUVIS) and offers services including design support, light‑exposure monitoring, and human‑centric daylight performance visualization.
SEED Biosciences SA
Since 2018 · 11–20 empl.
The core activity of SEED Biosciences SA is the development and provision of innovative solutions for single-cell assays, particularly in the areas of cell line development, CRISPR-mediated gene editing, rare cell isolation, and monoclonal antibody screening. The company offers products and technologies that enable researchers and scientists to precisely dispense and analyze single cells.
NewBiologix SA
Since 2022 · 11–20 empl.
The company's core activity lies in the development and application of technologies for gene and cell therapy, particularly in the areas of Next-Generation Sequencing (NGS), genomic analysis platforms, cell lines, and vector production. The company offers solutions for the development and manufacturing of cell and gene therapies and focuses on providing platforms and services to the biopharmaceutical industry.
ACTIVEN SA
Since 2010 · 1–10 empl.
The core activity of Activen SA is the research, development and production of innovative active ingredients for the dermo-cosmetic industry, particularly so-called miniproteins that specifically target cells and receptors in the body, thereby achieving skin-regenerating, anti-aging and protective effects.
Innoview Sàrl
Since 2016 · 1–10 empl.
Innoview Sàrl develops visual document security technologies and printing techniques such as dynamic colors, personalized dynamic colors, invisible full-color images (UV), dynamical moirés, smartphone-based authentication, daylight fluo watermarking and wide-gamut prints. The company is a spin-off of the École Polytechnique Fédérale de Lausanne (EPFL) and provides solutions for governmental and brand protection applications.
Archeotech S.A.
Since 1992 · 11–20 empl.3.0(2)
The core activity of Archéotech SA is the provision of services in the fields of archaeology, cultural heritage and surveying technology. Specifically, this includes: archaeological investigations and documentation of monuments, historical sites and cultural assets; surveying and documentation of buildings and facilities using modern technologies such as 3D scanning, photogrammetry and laser distance measurement; creation of 2D and 3D models, orthophotos and other visual representations of archaeological sites and monuments; analysis and interpretation of archaeological data and finds; preparation of reports and publications on archaeological research results; and development of solutions for the preservation and presentation of cultural assets and historical sites. The company offers its services both in Switzerland and abroad and positions itself as a specialist in the surveying and documentation of cultural assets and historical sites.
ADC Therapeutics SA
Since 2011 · 11–20 empl.5.0(1)
The core activity of ADC Therapeutics SA is the development and manufacturing of antibody-drug conjugates (ADCs), particularly for the treatment of cancer.
Alithea Genomics SA
Since 2020 · 11–20 empl.5.0(2)
The core activity of Alithea Genomics SA is the development and provision of solutions for the analysis and research of RNA data, particularly in the field of cancer research. The company offers products and services that enable the discovery of new biomarkers and the development of drugs, such as DRUG-seq and BRB-seq technologies. These solutions aim to simplify and accelerate the generation of 'big RNA data' to lay the foundation for future research and medicine.
Avenza Consulting Sàrl
Since 2024 · 1–10 empl.
The core activity of Avenza Consulting Sàrl is advising companies in the life science industry, particularly in the areas of strategy, research and development, program and portfolio management, as well as operational excellence. The company supports its clients in developing business strategies, market entry strategies, competitive analyses, drug development, clinical trials, regulatory strategies, and the analysis of complex data.
VivoArchitect Sàrl
Since 2024 · 1–10 empl.
VivoArchitect Sàrl is a preclinical Contract Research Organization (CRO) specializing in aging, healthspan and lifespan research. It provides validated in vivo models (including C57BL/6J and HET3 mice and killifish) and services such as experimental design, execution of preclinical in vivo studies, data analysis and scientific communication for biotech and pharmaceutical clients.
Novigenix AI SA
Since 2025 · 1–10 empl.
Novigenix AI SA develops liquid biopsy and multi-omics solutions based on the LITOSeek™ platform for immuno-transcriptomics analysis. The company uses AI and RNA data to discover biomarkers, predict therapy response, and support the development of cancer treatments.
TwinEdge Bioscience SA
Since 2025 · 1–10 empl.
TwinEdge Bioscience SA is a techbio company developing digital twins for oncology drug discovery and development. The company combines computational biology, artificial intelligence and personalized medicine to create digitally actionable tumor avatars for testing therapies and providing population‑scale translational insight for drug development decisions.
MoleSense Sàrl
Since 2025 · 1–10 empl.
MoleSense Sàrl develops a molecular wearable for maternity health monitoring before, during and after pregnancy. The company measures hormonal and inflammatory biomarkers non-invasively through sweat analysis to track biological changes over time.
Opna Bio Switzerland Sàrl
Since 2025 · 1–10 empl.
Opna Bio Switzerland Sàrl is a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer therapeutics. Its pipeline includes programs for multiple myeloma, myelofibrosis and other oncology targets.
ND BioSciences SA
Since 2019 · 1–10 empl.5.0(1)
ND BioSciences SA develops next-generation therapeutics and diagnostic assays for neurodegenerative diseases using validated and patented protein‑engineering and cellular drug‑discovery platforms. The company, a spin-off from the École polytechnique fédérale de Lausanne (EPFL), applies models that reproduce pathogenic protein aggregates and aggregation stages to support drug and biomarker development.
ANABIOTEC, à Evergem, succursale de Epalinges (VD)
Since 2025 · 1–10 empl.
ANABIOTEC, à Evergem, succursale de Epalinges (VD) provides analytical services for drug development, with a focus on CMC analytics and (pre-)clinical bioanalysis. The company supports method development, method validation, stability studies, characterization studies, and release testing for synthetic, biological, and cell and gene therapy products.
Synameta Therapeutics SARL
Since 2025 · 1–10 empl.
Synameta Therapeutics SARL develops an exosome-based platform for targeted therapeutic delivery. The company works on virus-free biovectors for applications in oncology and gene therapy.
Exciva Switzerland SA
Since 2026 · 1–10 empl.
Exciva Switzerland SA develops clinical-stage therapeutics for neuropsychiatric symptoms in Alzheimer’s disease dementia, with a focus on agitation. The company advances a lead drug program and conducts clinical studies related to Alzheimer’s disease.
Swiss Biotech Laboratories Europe Sàrl
Since 2026 · 1–10 empl.
Swiss Biotech Laboratories Europe Sàrl is a research and production unit active in biotechnology, analytical chemistry, and molecular biology. The company provides laboratory research, analytical services, contract research, and small-scale specialized production for clients in pharma, cosmetics, and biomedicine.
Pollux Scientific SA
Since 2022 · 1–10 empl.
The core activity of Pollux Scientific SA is the implementation of research projects in the field of synthetic biology and biocatalysis. The company provides scientific services, including the development of customized solutions for clients, and has its own laboratories for synthetic biology and molecular biocatalysis.
DDi Oncology Sàrl
Since 2016 · 1–10 empl.
Consultants in Science Sàrl
Since 2016 · 1–10 empl.
Eurêk-Invent Sàrl
Since 2020 · 1–10 empl.
BIORESSANT SARL
Since 2020 · 1–10 empl.
Orbis Medicines SA
Since 2022 · 1–10 empl.
VitalizeDx Sàrl
Since 2023 · 1–10 empl.
EpiKare Bio SA
Since 2025 · 1–10 empl.
Research & Development in Epalinges
Research & Development in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 11, 2026
Research & Development in other places
By canton